|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rustin G, van der Burg M, Griffin C, Qian
W and Swart AM: Early versus delayed treatment of relapsed ovarian
cancer. Lancet. 377:380–381. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Doubeni CA, Doubeni AR and Myers AE:
Diagnosis and management of ovarian cancer. Am Fam Physician.
93:937–944. 2016.PubMed/NCBI
|
|
4
|
Li Y, Zheng Q, Bao C, Li S, Guo W, Zhao J,
Chen D, Gu J, He X and Huang S: Circular RNA is enriched and stable
in exosomes: A promising biomarker for cancer diagnosis. Cell Res.
25:981–984. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang SJ, Chen X, Li CP, Li XM, Liu C, Liu
BH, Shan K, Jiang Q, Zhao C and Yan B: Identification and
characterization of circular RNAs as a new class of putative
biomarkers in diabetes retinopathy. Invest Ophthalmol Vis Sci.
58:6500–6509. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wilusz JE and Sharp PA: Molecular biology.
A circuitous route to noncoding RNA. Science. 340:440–441. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kumar L, Shamsuzzama, Haque R, Baghel T
and Nazir A: Circular RNAs: The emerging class of non-coding RNAs
and their potential role in human neurodegenerative diseases. Mol
Neurobiol. 54:7224–7234. 2017. View Article : Google Scholar
|
|
8
|
Piwecka M, Glazar P, Hernandez-Miranda LR,
Memczak S, Wolf SA, Rybak-Wolf A, Filipchyk A, Klironomos F, Jara
CAC, Fenske P, et al: Loss of a mammalian circular RNA locus causes
miRNA deregulation and affects brain function. Science.
357:eaam85262017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shan K, Liu C, Liu BH, Chen X, Dong R, Liu
X, Zhang YY, Liu B, Zhang SJ, Wang JJ, et al: Circular noncoding
RNA HIPK3 mediates retinal vascular dysfunction in diabetes
mellitus. Circulation. 136:1629–1642. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hsiao KY, Lin YC, Gupta SK, Chang N, Yen
L, Sun HS and Tsai SJ: Noncoding effects of circular RNA CCDC66
promote colon cancer growth and metastasis. Cancer Res.
77:2339–2350. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Guo Q, He Y, Sun L, Kong C, Cheng Y and
Zhang G: In silico detection of potential prognostic circRNAs
through a re-annotation strategy in ovarian cancer. Oncol Lett.
17:3677–3686. 2019.PubMed/NCBI
|
|
12
|
Xiong DD, Dang YW, Lin P, Wen DY, He RQ,
Luo DZ, Feng ZB and Chen G: A circRNA-miRNA-mRNA network
identification for exploring underlying pathogenesis and therapy
strategy of hepatocellular carcinoma. J Transl Med. 16:2202018.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Guan YJ, Ma JY and Song W: Identification
of circRNA-miRNA-mRNA regulatory network in gastric cancer by
analysis of microarray data. Cancer Cell Int. 19:1832019.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang L, Zhou Q, Qiu Q, Hou L, Wu M, Li J,
Li X, Lu B, Cheng X, Liu P, et al: CircPLEKHM3 acts as a tumor
suppressor through regulation of the miR-9/BRCA1/DNAJB6/KLF4/AKT1
axis in ovarian cancer. Mol Cancer. 18:1442019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gao Y, Zhang C, Liu Y and Wang M: Circular
RNA profiling reveals circRNA1656 as a novel biomarker in high
grade serous ovarian cancer. Biosci Trends. 13:204–211. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sheng M, Wei N, Yang HY, Yan M, Zhao QX
and Jing LJ: CircRNA UBAP2 promotes the progression of ovarian
cancer by sponging microRNA-144. Eur Rev Med Pharmacol Sci.
23:7283–7294. 2019.PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
18
|
Li J, Yang J, Zhou P, Le Y, Zhou C, Wang
S, Xu D, Lin HK and Gong Z: Circular RNAs in cancer: Novel insights
into origins, properties, functions and implications. Am J Cancer
Res. 5:472–480. 2015.PubMed/NCBI
|
|
19
|
Liu J, Song S, Lin S, Zhang M, Du Y, Zhang
D, Xu W and Wang H: Circ-SERPINE2 promotes the development of
gastric carcinoma by sponging miR-375 and modulating YWHAZ. Cell
Prolif. 52:e126482019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu G, Shi H, Deng L, Zheng H, Kong W, Wen
X and Bi H: Circular RNA circ-FOXM1 facilitates cell progression as
ceRNA to target PPDPF and MACC1 by sponging miR-1304-5p in
non-small cell lung cancer. Biochem Biophys Res Commun.
513:207–212. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu C, Zhang H and Liu H: Long noncoding
RNA UCA1 accelerates nasopharyngeal carcinoma cell progression by
modulating miR-124-3p/ITGB1 axis. Onco Targets Ther. 12:8455–8466.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fu W, Wu X, Yang Z and Mi H: The effect of
miR-124-3p on cell proliferation and apoptosis in bladder cancer by
targeting EDNRB. Arch Med Sci. 15:1154–1162. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cui RJ, Fan JL, Lin YC, Pan YJ, Liu C, Wan
JH, Wang W, Jiang ZY, Zheng XL, Tang JB and Yu XG: miR-124-3p
avail-ability is antagonized by LncRNA-MALAT1 for Slug-induced
tumor metastasis in hepatocellular carcinoma. Cancer Med.
8:6358–6369. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lv Y, Chen S, Wu J, Lin R, Zhou L, Chen G,
Chen H and Ke Y: Upregulation of long non-coding RNA OGFRP1
facilitates endometrial cancer by regulating miR-124-3p/SIRT1 axis
and by activating PI3K/AKT/GSK-3β pathway. Artif Cells Nanomed
Biotechnol. 47:2083–2090. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zeng B, Zhang X, Zhao J, Wei Z, Zhu H, Fu
M, Zou D, Feng Y, Luo H and Lei Y: The role of
DNMT1/hsa-miR-124-3p/BCAT1 pathway in regulating growth and
invasion of esophageal squamous cell carcinoma. BMC Cancer.
19:6092019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhao M, Hu X, Xu Y, Wu C, Chen J, Ren Y,
Kong L, Sun S, Zhang L, Jin R and Zhou X: Targeting of EZH2
inhibits epithelialmesenchymal transition in head and neck squamous
cell carcinoma via regulating the STAT3/VEGFR2 axis. Int J Oncol.
55:1165–1175. 2019.PubMed/NCBI
|
|
27
|
Nishimoto S, Hamajima Y, Toda Y, Toyoda H,
Kitamura K and Komurasaki T: Identification of a novel smooth
muscle associated protein, smap2, upregulated during neointima
formation in a rat carotid endarterectomy model. Biochim Biophys
Acta. 1576:225–230. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Maier S, Paulsson M and Hartmann U: The
widely expressed extracellular matrix protein SMOC-2 promotes
keratinocyte attachment and migration. Exp Cell Res. 314:2477–2487.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liu H, Sun Q, Sun Y, Zhang J, Yuan H, Pang
S, Qi X, Wang H, Zhang M, Zhang H, et al: MELK and EZH2 cooperate
to regulate medulloblastoma cancer stem-like cell proliferation and
differentiation. Mol Cancer Res. 15:1275–1286. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chen JF, Luo X, Xiang LS, Li HT, Zha L, Li
N, He JM, Xie GF, Xie X and Liang HJ: EZH2 promotes colorectal
cancer stem-like cell expansion by activating p21cip1-Wnt/β-catenin
signaling. Oncotarget. 7:41540–41558. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Karami Madani G, Rad A, Molavi M, Ardalan
Khales S, Abbaszadegan MR and Forghanifard MM: Predicting the
correlation of EZH2 and cancer stem cell markers in esophageal
squamous cell carcinoma. J Gastrointest Cancer. 49:437–441. 2018.
View Article : Google Scholar
|
|
32
|
Zhang H, Qi J, Reyes JM, Li L, Rao PK, Li
F, Lin CY, Perry JA, Lawlor MA, Federation A, et al: Oncogenic
deregulation of EZH2 as an opportunity for targeted therapy in lung
cancer. Cancer Discov. 6:1006–1021. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Stazi G, Zwergel C, Mai A and Valente S:
EZH2 inhibitors: A patent review (2014-2016). Expert Opin Ther Pat.
27:797–813. 2017. View Article : Google Scholar : PubMed/NCBI
|
